Evidence map›Paper›PMID 42368702›Full record

ArticleJAC-antimicrobial resistance2026

Pre-emptive versus empirical antifungal therapy in patients with febrile neutropenia with acute leukaemia: a GIMEMA study.

Alessandra Micozzi, Giuseppe Gentile, Marco Picardi, Clara Minotti, Stelvio Ballanti, Mario Delia, Federico Simonetti, Bruno Martino, Antonella Ferrari, Francesco Lanza and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Alessandra MicozziEmatologia, Dipartimento di Medicina Traslazionale e di Precisione, Sapienza Università di Roma, Roma, Italy.ORCID https://orcid.org/0000-0003-1358-6680
Giuseppe GentileEmatologia, Dipartimento di Medicina Traslazionale e di Precisione, Sapienza Università di Roma, Roma, Italy.
Marco PicardiDipartimento di Medicina Clinica e Chirurgia, Università Federico II, Napoli, Italy.
Clara MinottiDipartimento di Ematologia Oncologia e Dermatologia, Azienda Policlinico Umberto I di Roma, Roma, Italy.
Stelvio BallantiEmatologia e TMO, Azienda Ospedaliera di Perugia, Ospedale S. M. Della Misericordia, Perugia, Italy.
Mario DeliaEmatologia e Trapianto di Cellule Staminali, Azienda Ospedaliero-Universitaria-Consorziale (AOUC) Policlinico di Bari, Bari, Italy.
Federico SimonettiAzienda USL Toscana Nord Ovest, UOC Ematologia Aziendale Ospedale Versilia, Lido di Camaiore, Italy.
Bruno MartinoDipartimento di Emato-Oncologia e Radioterapia, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
Antonella FerrariEmatologia, Azienda Ospedaliera Universitaria Sant'Andrea, Dipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Roma, Italy.
Francesco LanzaDipartimento Universitario DIMEC, Alma Mater Università di Bologna, Ematologia, Ospedale di Ravenna, Ravenna, Italy.
Angelo M CarellaEmatologia e Centro Trapianti, Fondazione Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy.
Prassede SalutariEmatologia, Dipartimento Oncologico Ematologico, Ospedale di Pescara, Pescara, Italy.
Lorella M A MelilloEmatologia, Policlinico di Foggia, Foggia, Italy.
Monica BocchiaEmatologia, Università di Siena, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.
Mario LuppiEmatologia, Policlinico di Modena, Modena, Italy.ORCID https://orcid.org/0000-0002-0373-1154
Mara MerluzziEmatologia ed Immunologia Clinica, Dipartimento di Medicina e Chirurgia, Università degli Studi di Perugia, Perugia, Italy.
Giampaolo BucaneveMedicina Interna e Scienze Oncologiche, Azienda Ospedaliera di Perugia-Centro Regionale di Farmacovigilanza, Regione Umbria, Perugia, Italy.
Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program Working Party

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To compare the efficacy of pre-emptive antifungal therapy (PAT) and empirical antifungal therapy (EAT) in patients with febrile neutropenic acute leukaemia (AL) with/without anti-mold prophylaxis. Methods: We included 92 patients with AL and neutropenia with fever unresponsive to empiric antibiotics, stratified by posaconazole prophylaxis to receive EAT ( Results: Posaconazole prophylaxis was equally distributed among the patients (overall 55.4%). Antifungal therapy was started in 58% of the patients in the PAT group versus 100% in the EAT group ( Conclusions: In patients with persistently febrile neutropenic AL, PAT was safe and effective and reduced the use and costs of antifungals, irrespective of anti-mold prophylaxis, compared with empirical treatment.

Identifiers

PMID42368702
PMCPMC13308701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.